AbbVie Inc Investor Relations Material
AbbVie Inc. discovers and develops pharmaceuticals worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat chronic lymphocytic leukemia (CLL), Waldenstrom's macroglobulinemia, and mantle cell lymphoma; VIEKIRA PAK, an interferon-free therapy to treat genotype 1 chronic hepatitis C virus infection in adults; TECHNIVIE for use in combination with ribavirin to treat genotype 4 chronic hepatitis C virus infection in adults without cirrhosis; VIEKIRX used with ribavirin for the treatment of genotype 1b chronic hepatitis C virus in patients without cirrhosis; and MAVYRET to treat chronic HCV genotype 1-6 infection
Upcoming events for
Q3 20222022-10-28
Latest company events
Ticker symbol
ABBV
Country
United States of America
About the company
Investor Relations Page
Dig deeper into the AbbVie Inc fundamentals on Quartr.
- Skip straight to the Q&A session
- Receive notifications about new events
- Connect the financial calender on your phone
- Figure out why the stock is up or down
- Read the transcripts or scroll the deck
- Access earnings or press releases
